%0 Journal Article
%T Role of hypoxia-inducible factor 1 in type 1 diabetes.
%A Fagundes RR
%A Zaldumbide A
%A Taylor CT
%J Trends Pharmacol Sci
%V 45
%N 9
%D 2024 Sep 9
%M 39127527
%F 17.638
%R 10.1016/j.tips.2024.07.001
%X Type 1 diabetes (T1D) is a common autoimmune disease in which dysregulated glucose metabolism is a key feature. T1D is both poorly understood and in need of improved therapeutics. Hypoxia is frequently encountered in multiple tissues in T1D patients including the pancreas and sites of diabetic complications. Hypoxia-inducible factor (HIF)-1, a ubiquitous master regulator of the adaptive response to hypoxia, promotes glucose metabolism through transcriptional and non-transcriptional mechanisms and alters disease progression in multiple preclinical T1D models. However, how HIF-1 activation in β-cells of the pancreas and immune cells (two key cell types in T1D) ultimately affects disease progression remains controversial. We discuss recent advances in our understanding of the role of hypoxia/HIF-1-induced glycolysis in T1D and explore the possible use of drugs targeting this pathway as potential new therapeutics.